Filing Details

Accession Number:
0000899243-22-018913
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-19 18:01:05
Reporting Period:
2022-05-17
Accepted Time:
2022-05-19 18:01:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1847903 Centessa Pharmaceuticals Plc CNTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1861878 Antoine Yver C/O Centessa Pharmaceuticals Plc
3Rd Fl., 1 Ashley Rd, Altrincham
Cheshire X0 WA14 2DT
Evp & Chairman Of Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2022-05-17 20,222 $5.42 813,675 No 4 S Direct
Ordinary Shares Disposition 2022-05-18 64,778 $5.10 748,897 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted shares and does not represent a discretionary trade by the Reporting Person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.26 to $5.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.